Description
Regorafenib, marketed under the brand name STIVARGA, It is an prescription medication that has been approved by the US FDA in September 2012. In February 2013 the US FDA expanded the approved use to treat patients with advanced gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease.
What is Regorafenib (Regorafenib) ?
STIVARGA (regorafenib) tablets, oral Initial U.S. Approval: 2012.
Stivarga is a kinase inhibitor indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an antiVEGF therapy, and, if KRAS wild type, an anti-EGFR therapy.
Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.
How to order approved “Regorafenib (Regorafenib) for tablets” Medicine?
STIVARGA (Regorafenib) tablets is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing STIVARGA and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
